STAT+: Pharmalittle: We're reading about cheap generic obesity drugs in India, high demand for estrogen patches and more

Here’s a number that should make you angry, or at least frustrated: $14. That’s what a month of semaglutide costs in India right now. Novo Nordisk’s Indian patent expired on March 20, 2026, and generic manufacturers moved fast. Multiple companies are producing semaglutide at $14 to $15 per month. In the U.S., a month of Wegovy lists at over $1,300.

Same molecule. Same mechanism. A 99% price difference.

The obvious question is when U.S. patients get access to generic semaglutide. The answer isn’t encouraging. Novo Nordisk’s American patents don’t expire until 2033 at the earliest, with some extending to 2037. That’s seven to eleven years of brand-name pricing. Even after patent expiry, FDA approval for biosimilar or generic GLP-1 injectables takes additional time. You’re realistically looking at 2035 or later before a true generic semaglutide injection hits U.S. pharmacies.

So what are your actual options today? The closest thing to patent-cliff pricing in the U.S. comes from two places. First, Lilly’s Foundayo (orforglipron) launched at $149/month for self-pay patients. It’s an oral GLP-1, not semaglutide, but it’s the cheapest branded GLP-1 on the market. Second, the Zepbound KwikPen starts at $299/month through Lilly’s self-pay savings card. Both are brand-name products from Eli Lilly, not generics, but their pricing reflects the competitive pressure that cheap international alternatives are creating.

Compounded semaglutide from telehealth providers like SkinnyRx and Henry Meds has filled the gap for many patients at $150 to $300 per month. But the FDA’s ongoing crackdown on compounding pharmacies makes this supply uncertain. The gap between $14 in India and $1,300 in the U.S. isn’t a market failure that will resolve on its own. It’s a patent system working exactly as designed, for better or worse. Until 2033, you’re navigating savings cards, compounders, and telehealth providers rather than walking into a pharmacy for a $14 generic. Our cost calculator can help you compare what you’d actually pay across these options.

Source: STAT News

Frequently asked questions

Can I buy generic semaglutide from India and import it to the U.S.?

Technically, the FDA allows personal importation of a 90-day supply of medications not available domestically under certain conditions, but semaglutide IS available domestically (as Wegovy and Ozempic), which complicates this pathway. Importing prescription medications without an FDA-approved label carries risks: you can’t verify purity, dosing, or storage conditions. Some patients do purchase from international pharmacies, but it’s a legal gray area with real safety concerns. It’s not something we recommend without consulting your physician.

When will generic semaglutide be available in the U.S.?

Novo Nordisk’s core U.S. patents on semaglutide expire between 2033 and 2037. After expiry, generic or biosimilar manufacturers would need FDA approval, which typically adds 1 to 3 years. A realistic estimate for affordable generic semaglutide at U.S. pharmacies is 2035 to 2040. In the meantime, oral GLP-1 options like Foundayo at $149/month and the Zepbound KwikPen at $299/month are the most affordable branded alternatives.

Why is there such a huge price difference between India and the U.S.?

India doesn’t recognize the same patent protections as the U.S. for many pharmaceuticals, and Indian patent law includes provisions for compulsory licensing that allow generic production even before patent expiry. The Indian generic price of $14/month likely reflects manufacturing cost plus a small margin. The U.S. price of $1,300+ reflects patent monopoly pricing, R&D cost recovery, and the structure of the American insurance system where high list prices fund rebates to pharmacy benefit managers. The actual manufacturing cost of semaglutide is estimated at $10 to $30 per month.

Keep reading

• GLP-1 cost calculator
• Branded vs compounded GLP-1: U.S. market reality
• SkinnyRx: Provider profile and pricing
• Foundayo: Full medication profile